Using 'dead or dependent' as an outcome measure in clinical trials in Parkinson's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 2, 2015, Pages 180-185

  McGhee, David ^a   Parker, Alexander ^a   Fielding, Shona ^a   Zajicek, John ^b   Counsell, Carl ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL (TOPIC); DAILY LIFE ACTIVITY; DEAD OR DEPENDENT; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PARKINSON DISEASE; RISK FACTOR; RISK REDUCTION; SAMPLE SIZE; SURVIVAL RATE; VERY ELDERLY; KAPLAN MEIER METHOD; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY;

NEUROPROTECTIVE AGENT;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SAMPLE SIZE;

EID: 84921405698     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-307703     Document Type: Article

References (21)

1. World Health Organization. International classification of impairments, disabilities and handicaps. Geneva, Switzerland: World Health Organization, 1980.
2. Fahn S, Eton RL, UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson's Disease. Volume 2. New Jersey: Florham Park, Macmillan Healthcare Information, 1987:153-63.
3. Schwab R, England A. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham F, Donaldson I, eds. Third Symposium on Parkinson's Disease. Edinburgh: E&S Livingstone, 1969:152-7.
4. Jenkinson C, Fitzpatrick R, Peto V, et al. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997;26:353-7.
5. ICF. Towards a common language for functioning, disability and health. The International Classification of Functioning, Disability and Health. Geneva: World Health Organisation, 2002. http://www.who.int/classifications/icf/training/icfbeginnersguide.pdf (accessed 12 Jan 2014).
6. Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clincial trials: a literature review and synthesis. Stroke 2007;38:1091-6.
7. Mahoney F, Barthel D. Functional evaluation: the Barthel index. Md State Med J 1965;14:61-5.
8. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-81.
9. Caslake R, Taylor K, Scott N, et al. Age-, gender-, and socioeconomic status-specific incidence of Parkinson's disease and parkinsonism in North East Scotland: The PINE study. Park Rel Dis 2013;19:515-21.
10. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
11. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-53.
12. Elm JJ, Goetz CG, Ravina B, et al. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol 2007;57:197-203.
13. Clarke CE. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs? Mov Disord 2004;19:491-8.
14. Rascol O. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design. Neurology 2009;72:S51-8.
15. Clarke CE. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Mov Disord 2008;23:784-9.
16. Pa˚lhagen S, Heinonen E, Hägglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006;66:1200-6.
17. Lauer MS, D'Agostino RB Sr. The randomized registry trial - the next disruptive technology in clinical research? N Engl J Med 2013;369:1579-81.
18. Mitchell SL, Sullivan EA, Lipsitz LA. Exclusion of elderly subjects from clinical trials for Parkinson disease. Arch Neurol 1997;54:1393-8.
19. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003;18:738-50.
20. Wardlaw JM, Murray V, Berge E, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009;4: CD000213. doi:0.1002/14651858.CD000213.pub2.
21. Hofmeijer J, Kappelle LJ, Algra A, et al. Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial. Lancet Neurol 2009;8:326-33.